These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 14636615

  • 1. Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma.
    Kawano K, Goto H, Kanda T, Yanagisawa S.
    Int J Oral Maxillofac Surg; 2003 Dec; 32(6):633-7. PubMed ID: 14636615
    [Abstract] [Full Text] [Related]

  • 2. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
    Kawasaki G, Yoshitomi I, Yanamoto S, Mizuno A.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Dec; 94(6):717-23. PubMed ID: 12464897
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity.
    Koga M, Anegawa E, Yoh J, Tsuyama H, Sakaino H, Iwamoto O, Koga C, Kusukawa J.
    Br J Oral Maxillofac Surg; 2010 Mar; 48(2):88-93. PubMed ID: 19576666
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].
    Kawasaki G, Yoshitomi I, Yanamoto S, Yamada S, Kawano T, Mizuno A.
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1035-9. PubMed ID: 20567103
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
    Harada K, Kawashima Y, Yoshida H, Sato M.
    Anticancer Res; 2006 Jun; 26(2B):1615-9. PubMed ID: 16619581
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical expression of thymidylate synthase as a prognostic factor and as a chemotherapeutic efficacy index in patients with colorectal carcinoma.
    Tachikawa D, Arima S, Futami K.
    Anticancer Res; 2000 Jun; 20(6A):4103-7. PubMed ID: 11131679
    [Abstract] [Full Text] [Related]

  • 11. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
    Uyama R, Yoshizawa Y, Tajiri T, Endo Y, Mitsuya T, Sanada Y.
    Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
    [Abstract] [Full Text] [Related]

  • 12. High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
    Harada K, Supriatno, Kawaguchi S, Kawashima Y, Itashiki Y, Yoshida H, Sato M.
    Anticancer Res; 2005 May; 25(3c):2471-5. PubMed ID: 16080478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
    Kobayashi H, Koike T, Nakatsuka A, Kurita H, Sagara J, Taniguchi S, Kurashina K.
    Oral Oncol; 2005 Jan; 41(1):38-47. PubMed ID: 15598584
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
    Nakazawa M, Ohnishi T, Ohmae M, Chisoku H, Yui S, Iwai S, Sumi T, Fukuda Y, Kishino M, Yura Y.
    Int J Clin Pharmacol Res; 2005 Jan; 25(3):115-22. PubMed ID: 16366419
    [Abstract] [Full Text] [Related]

  • 20. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, Ueyama Y.
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.